How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cytology and HPV Testing Market
- By Test Type: Pap Smear Test, HPV DNA Test, Liquid-Based Cytology, Visual Inspection with Acetic Acid (VIA), HPV mRNA Test
- By Sample Type: Cervical Swab, Vaginal Swab, Urine Sample, Self-Collected Samples
- By Technology: Polymerase Chain Reaction (PCR), Hybrid Capture II, Signal Amplification Assays, Next-Generation Sequencing (NGS), Immunocytochemistry
- By End User: Hospitals, Diagnostic Laboratories, Clinics, Research Institutes, Specialty Cancer Centers
- By Application: Cervical Cancer Screening, HPV Genotyping, Pre-cancerous Lesion Detection, Post-Treatment Monitoring, Research and Development
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pap Smear Test leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Cytology and HPV Testing Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Sample Type 4
Technology 5
End User 5
Application 5
Companies profiled
Hologic Inc.
Roche Diagnostics
Qiagen N.V.
BD (Becton
Dickinson and Company)
Abbott Laboratories
Danaher Corporation
Siemens Healthineers
PerkinElmer Inc.
F. Hoffmann-La Roche AG
bioMérieux SA
Hain Lifescience GmbH
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Qiagen N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Danaher Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →bioMérieux SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hain Lifescience GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Becton Dickinson and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Genomica S.A.U.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →NIPRO Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sekisui Medical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,783M by 2033 · 9.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pap Smear Test28.5
- HPV DNA Test21.1
- Liquid-Based Cytology11.1
- Visual Inspection with Acetic Acid (VIA)20.0
- HPV mRNA Test19.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,448M → $3,154M · 10.2%
Europe$1,009M → $1,924M · 8.4%
Asia Pacific$921.4M → $1,685M · 7.8%
Latin America$570.4M → $1,135M · 9.0%
Middle East and Africa$438.7M → $889.0M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.012026
9.022027
9.042028
9.052029
9.062030
9.082031
9.082032
9.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hologic Inc.14.1
- Roche Diagnostics18.3
- Qiagen N.V.10.3
- BD (Becton11.5
- Dickinson and Company)6.8
- Abbott Laboratories11.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type26.6%
Sample Type17.6%
Technology15.2%
End User28.0%
Application12.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.9
- Europe21.9
- Asia Pacific19.2
- Latin America12.9
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hologic Inc. | 97 | 81 | 82 | 81 | 88 | 97 | 88 |
| Roche Diagnostics | 92 | 84 | 91 | 92 | 87 | 87 | 89 |
| Qiagen N.V. | 83 | 82 | 66 | 72 | 82 | 78 | 77 |
| BD (Becton | 62 | 57 | 63 | 63 | 78 | 81 | 67 |
| Dickinson and Company) | 63 | 54 | 71 | 66 | 63 | 68 | 64 |
| Abbott Laboratories | 58 | 47 | 50 | 49 | 51 | 61 | 53 |
| Danaher Corporation | 56 | 48 | 44 | 61 | 60 | 41 | 52 |
| Siemens Healthineers | 56 | 55 | 42 | 44 | 44 | 45 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hologic Inc.
- Roche Diagnostics
- Qiagen N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hologic Inc. | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Roche Diagnostics | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Qiagen N.V. | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| BD (Becton | − | ◐ | ◐ | − | ✓ | ✓ |
| Dickinson and Company) | − | − | ◐ | ◐ | − | ◐ |
| Abbott Laboratories | ◐ | − | − | ◐ | − | ◐ |
| Danaher Corporation | − | − | − | ◐ | ◐ | − |
| Siemens Healthineers | ◐ | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics89
2Hologic Inc.88
3Qiagen N.V.77
4BD (Becton67
5Dickinson and Company)64
6Abbott Laboratories53
7Danaher Corporation52
8Siemens Healthineers48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Hologic Inc.Roche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Qiagen N.V.BD (Becton
Contender1
Focused players with pockets of strength.
Dickinson and Company)
Niche3
Specialists in a single segment or region.
Abbott LaboratoriesDanaher CorporationSiemens Healthineers
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Cytology and HPV Testing Market — a $560M beachhead inside a $9.95B market.
Beachhead (SOM)$560Mobtainable near-term
Serviceable (SAM)$3.67Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Pap Smear Test
Best fit — highest urgency & budget in Test Type.
Economic buyer77 fit
HPV DNA Test
Strong fit — clear ROI and a fast path to value.
End user67 fit
Liquid-Based Cytology
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cytology and HPV Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified23%
Evaluation13%
Closed-won6%
$12.0KCAC
$45KLTV
3.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cytology and HPV Testing Market is a durable-growth opportunity — $5.48B by 2033, compounding at 10.0%.
TAM · 2025$2.56Btoday
TAM · 2033$5.48Bforecast
CAGR10.0%2027–2033
Cumulative$34.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.48BTotal addressable market
SAM$1.93BServiceable available market
SOM$369MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.0% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.48BLarge & growingTAM by 2033 at 10.0% CAGR
$1.93BServiceable nowreachable with today’s model
$369MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.28BBear6.5% CAGR
$5.48BBase10.0% CAGR
$7.02BBull13.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cytology and HPV Testing Market — a $2.08B market by 2033. Plan: grow share from 10.8% to 17.9%.
Market size · 2033$2.08Btotal addressable
Market CAGR11.1%2027–2033
Target share17.9%from 10.8% today
Revenue ambition$372Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 17.9% | On track |
| Revenue | $207M | $372M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 32.6% | 45.8% | At risk |
| Customer retention | 87.1% | 93.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $56M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cytology and HPV Testing Market conversation — a $8.69B market you can size, segment and defend in minutes.
Market size · 2033$8.69Btotal opportunity
Growth5.7%CAGR to 2033
Addressable buyers1,158+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 4 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Hologic Inc.Roche DiagnosticsQiagen N.V.BD (BectonDickinson and Company)Abbott LaboratoriesDanaher CorporationSiemens Healthineers+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cytology and HPV Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cytology and HPV Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →D-dimer Testing Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportDental Membrane and Bone Graft Substitutes Market
Market size, share, segmentation and regional forecast.
$493M market · 2025 base year
View reportDermatology Diagnostic Devices and Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportDiabetic Foot Ulcers and Pressure Ulcers Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportDiagnostic Testing of STDs Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportDialysis Products and Services Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportDigestive Enzymes Market
Market size, share, segmentation and regional forecast.
$972M market · 2025 base year
View reportDigital Therapeutic Devices Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportDrug and Gene Delivery Systems Market
Market size, share, segmentation and regional forecast.
$991M market · 2025 base year
View reportDrug Delivery Systems Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportDry Eye Disease Market
Dry Eye Disease Market is valued at USD 5.12 Billion in 2025 and is expected to reach USD 7.55 …
$5.1B market · 2025 base year
View reportECG Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.